Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14294016 | 1.00 | KMT2A (0.46) | KMT2AMAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL13198897 | 0.95 | KMT2A (0.51) | KMT2AMAPTALDH1A1L3MBTL1ATM | |
| SCHEMBL5198204 | 0.93 | KMT2A (0.54) | KMT2AMAPTALDH1A1L3MBTL1ATM | |
| SCHEMBL12483549 | 0.85 | POLB (0.63) | KMT2AL3MBTL1POLBTSHRRAB9A | |
| SCHEMBL12482314 | 0.85 | POLB (0.63) | KMT2AL3MBTL1POLBTSHRRAB9A | |
| SCHEMBL28158667 | 0.85 | POLB (0.63) | KMT2AL3MBTL1POLBTSHRRAB9A | |
| SCHEMBL9220591 | 0.85 | KDM4E (0.47) | KMT2AMAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL20693641 | 0.85 | KDM4E (0.47) | KMT2AMAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL792002 | 0.84 | HDAC8 (0.44) | L3MBTL1POLBTSHRRAB9A | |
| SCHEMBL30821937 | 0.84 | POLB (0.43) | MAPTL3MBTL1POLBTSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | KMT2A 3825/4885MAPT 4309/4885ALDH1A1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.